Tempus AI (TEM) reported Q2 2026 earnings after the bell July 30. CEO Eric Lefkofsky and CFO Jim Rogers discussed quarter performance and outlook on the call.
Tempus AI reported second-quarter 2026 results after the bell Tuesday. The precision medicine company, which uses artificial intelligence to analyze clinical and genomic data, released its financials in a press statement posted to its investor relations site. CEO Eric Lefkofsky and CFO Jim Rogers hosted the conference call alongside Vice President of Investor Relations Elizabeth Krutoholow.
Krutoholow opened the call by directing listeners to the earnings release and an updated investor presentation. “Tempus released results for the quarter ended June 30, 2026,” she said. “The press release and overview of the quarter and our latest presentation are available on our IR website.” She also cautioned that management would make forward-looking statements subject to risks detailed in the company’s 10-K and other SEC filings.
The call drew analysts from seven firms, including Kallum Titchmarsh of Morgan Stanley (MS), Bradley Bowers of Mizuho, Kyle Mikson of Canaccord Genuity, Matthew Shea of Needham, Mark Massaro of BTIG, Robert Bamberger of Baird, and Brendan Smith of TD Cowen.
Tempus has built a business around AI-powered diagnostics, data platforms, and clinical trial matching. The company went public in 2024 and has focused on expanding its installed base of hospital partners and growing its genomic testing volumes. Full details from the second quarter are in the earnings release and the accompanying slide deck.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.